PHOTO ROUNDS

Nodule on the left cheek

Often mistaken for a cyst or acneiform lesion, this lesion is actually quite aggressive—and worrisome.

AN 85-YEAR-OLD MAN with a history of skin cancer presented to my dermatology practice (NT) for evaluation of a "pimple" on his left cheek that failed to resolve after 2 months (FIGURE). The patient noted that the lesion had grown, but that he otherwise felt well.

On examination, the lesion was plum colored, and the area was firm and nontender to palpation. The patient was referred to a plas-

tic surgeon for an excisional biopsy to clarify the nature of the lesion.

- WHAT IS YOUR DIAGNOSIS?
- O HOW WOULD YOU TREAT THIS PATIENT?

FIGURE



Melissa M. Warne, BS; Nathmal S. Tarfare, MD Albany Medical College, NY (Ms. Warne); Nathmal S. Tarfare MD, PC, Hamburg, NY

warnem@amc.edu

The authors reported no potential conflict of interest relevant to this article.

doi: 10.12788/jfp.0339

Diagnosis: Merkel cell carcinoma

A biopsy performed 2 weeks after the initial visit confirmed the clinical suspicion for Merkel cell carcinoma (MCC).

MCC is a cutaneous neuroendocrine malignancy. Although its name acknowledges similarities between the tumor cells and Merkel cells, it is now considered unlikely that Merkel cells are the actual cells of origin.¹

The majority of MCCs are asymptomatic despite rapid growth and are typically red or pink and occur on UV-exposed areas, as in our patient.² A cyst or acneiform lesion is the single most common diagnosis given at the time of biopsy.²

■The incidence of MCC is greatest in people of advanced age and in those who are immunosuppressed. In the United States, the estimated annual incidence rate rose from 0.5 cases per 100,000 people in 2000 to 0.7 cases per 100,000 people in 2013.³ MCC increases exponentially with advancing age, from 0.1 (per 100,000) in those ages 40 to 44 years to 9.8 in those older than 85 years.³ The growing cohort of ageing baby boomers and the increased number of immunosuppressed individuals in the community suggest that clinicians are now more likely to encounter MCC than in the past.

■ While UV radiation is highly associated with MCC, the major causative factor is considered to be Merkel cell polyomavirus (MCPyV).¹ In fact, MCPyV has been linked to 80% of MCC cases.¹³ Most people have positive serology for MCPyV in early childhood, but the association between MCC and old age highlights the impact of immunosuppression on MCPyV activity and MCC development.¹

Clinical suspicion is the first step in diagnosing MCC

The mnemonic AEIOU highlights the key clinical features of this aggressive tumor^{2,4}:

- Asymptomatic
- Expanding rapidly (often grows in less than 3 months)
- Immune suppression (eg, chronic lymphocytic leukemia, solid organ transplant patient)
- Older than 50
- **U**V exposure on fair skin.

If a lesion is suspected to be MCC, the

next step includes biopsy so that a definitive diagnosis can be made. A firm, nontender nodule that lacks fluctuance should raise suspicion for a neoplastic process.

The differential is broad, ranging from cysts to melanoma

The differential diagnosis for an enlarging, plum-colored nodule on sun-exposed skin includes an abscess, a ruptured or inflamed epidermoid cyst, basal cell carcinoma, squamous cell carcinoma, and malignant melanoma.

- An abscess is typically tender and expands within a matter of days rather than months.
- A cyst can be ruled out by the clinical appearance and lack of an overlying pore.
- Basal cell carcinoma can be characterized by a rolled border and central ulceration.
- Squamous cell carcinomas often exhibit a verrucous surface with marked hyperkeratosis.
- Melanoma manifests with brown or irregular pigmentation and may be associated with a precursor lesion.

Tx includes excision and consistent follow-up

Complete excision is the critical first step to successful therapy. Sentinel lymph node studies are typically performed because of the high incidence of lymph node metastasis. Frequent follow-up is required because of the high risk of recurrent or persistent disease.

Local recurrence usually occurs within 1 year of diagnosis in more than 40% of patients.⁵ Distant metastasis can be treated with a programmed cell death ligand 1 blocking agent (avelumab) or a programmed cell death protein 1 inhibitor (nivolumab or pembrolizumab).⁶

al cancer center for sentinel lymph node evaluation, where he was found to have nodal disease. The patient was put on pembrolizumab and received radiation therapy but showed only limited response. Seven months after diagnosis, he passed away from metastatic MCC.

>

The growing

ageing baby

boomers and

the increased

number of

pressed individuals in

immunosup-

cohort of

the community suggest that clinicians are now more likely to encounter MCC than in the past.

REFERENCES

- Pietropaolo V, Prezioso C, Moens U. Merkel cell polyomavirus and Merkel cell carcinoma. Cancers (Basel). 2020;12:1774. doi: 10.3390/cancers12071774
- Heath M, Jaimes N, Lemos B, et al. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J Am Acad Dermatol. 2008;58:375-381. doi: 10.1016/j.jaad.2007.11.020
- Paulson KG, Park SY, Vandeven NA, et al. Merkel cell carcinoma: current US incidence and projected increases based on changing demographics. J Am Acad Dermatol. 2018;78:457-463.e2. doi: 10.1016/j.jaad.2017.10.028
- 4. Voelker R. Why Merkel cell cancer is garnering more attention. JAMA. 2018;320:18-20. doi: 10.1001/jama.2018.7042
- Allen PJ, Browne WB, Jacques DP, et al. Merkel cell carcinoma: prognosis and treatment of patients from a single institution. *J Clin Oncol*. 2005;23:2300-2309. doi: 10.1200/JCO.2005.02.329
- D'Angelo SP, Russell J, Lebbé C, et al. Efficacy and safety of firstline avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma: a preplanned interim analysis of a clinical trial. JAMA Oncol. 2018;4:e180077. doi: 10.1001/ jamaoncol.2018.0077




Visit us @ mdedge.com/familymedicine



A Special Supplement to The Journal of Family Practice®

Hot Topics in Primary Care 2021

In this year's Hot Topics in Primary Care, experts address new advances in pharmacologic treatment, as well as provide important strategies to reduce cardiovascular risk and improve overall patient management. Learn more on communication techniques and office practices.



Look for this supplement at mdedge.com/familymedicine/HotTopics2021



This supplement was sponsored by Primary Care Education Consortium and Primary Care Metabolic Group. It was edited and peer reviewed by *The Journal of Family Practice*.

CREDITS